Tapentadol
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
Tapentadol: Migraine disorder
One-Sentence Summary
Tapentadol is a centrally acting opioid analgesic marketed in Australia as Palexia SR. The TxGNN model predicts it may be effective for migraine disorder, but there are currently no registered clinical trials and no publications directly supporting this use. This is a model-only prediction, and the available literature points more towards safety concerns than benefit.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 0.9967 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the compiled data. Based on general pharmacological knowledge, tapentadol is a mu-opioid receptor agonist and norepinephrine reuptake inhibitor. Its efficacy in pain conditions is established, and the model likely links it to migraine through this analgesic profile.
The high TxGNN score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. Opioids are generally not recommended for migraine because of the risk of medication-overuse headache, poorer outcomes, and limited efficacy. The related prediction for migraine with brainstem aura appears to reflect the same learned similarity.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
No literature was retrieved for “migraine disorder” itself.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 29760569 | 2018 | Cohort | Drug Healthc Patient Saf | Opioids are not recommended for routine migraine treatment because of medication-overuse headache and dependence risks. Concomitant opioid use with triptans or serotonergic antidepressants carries a serotonin syndrome warning. |
| 33689517 | 2021 | Review | Expert Opin Pharmacother | Reviews NSAIDs and acetaminophen as alternatives to opioids for acute pain. |
| 29616344 | 2018 | Review | Curr Pain Headache Rep | Reviews non-opioid therapies for chronic pain. |
| 28729524 | 2017 | Case report | Am J Case Rep | Cardiac arrest after intravenous tapentadol abuse in a patient presenting with headache. This is a safety signal, not evidence of efficacy. |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 10091D | Palexia SR | Tablet (modified release) 200 mg (as hydrochloride) | Not stated in the compiled data |
Safety Considerations
- Drug Interactions: 100 interactions were identified in the interaction screen. Examples of Major interactions include bupropion, morphine, lorcaserin, diethylpropion, dolasetron, palonosetron and phentermine. Examples of Moderate interactions include epinephrine, naloxone, eluxadoline, dronabinol, nabilone, and several anticholinergic agents (hyoscyamine, atropine, glycopyrronium, dicyclomine, trospium).
- Migraine-specific concerns: Tapentadol’s serotonergic and noradrenergic activity raises a potential serotonin syndrome concern with triptans and serotonergic antidepressants. Opioids also carry a risk of medication-overuse headache.
- Other: Published reports describe abuse and nonmedical use of tapentadol.
Please refer to the TGA-approved Product Information (PI) for full warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on model score alone (L5), with no trials and no direct literature. Clinical guidance and the indirect literature argue against opioids in migraine because of medication-overuse headache and serotonin syndrome risks, so the risk-benefit balance appears unfavourable.
To proceed, the following is needed:
- Mechanism of action data to support a migraine-specific rationale
- Approved indication and safety text from the TGA Product Information (the compiled data contained none)
- Controlled clinical evidence of tapentadol in migraine, compared against current standard therapies
- Assessment of medication-overuse headache and serotonin syndrome risk, particularly with triptans
- Consideration of whether any other predicted indication (for example, pain-related comorbidity) is more clinically plausible
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.